Allergan Plc AGN, +0.84% said Tuesday it has agreed to acquire Tobira Therapeutics Inc. tbra in a deal valued at up to $1.7 billion. Allergan will pay $28.35 per Tobira share upfront, and up to $49.84 per share in contingent value rights, that are payable on the meeting of certain milestones.
http://www.marketwatch.com/story/allergan-to-buy-tobira-in-deal-valued-at-up-to-17-billion-2016-09-20
Galmed Medical Research Ltd., Genfit Corp., Novartis AG, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, or Takeda, Raptor Pharmaceutical Corp., Immuron Ltd., Shire plc and Conatus Pharmaceuticals Inc.
http://www.nasdaq.com/markets/ipos/company/tobira-therapeutics-inc-754412-75811
The Quote Overview page gives you a snapshot view for a specific symbol. Real-time prices are provided by Bats Exchange on individual U.S. equities quote pages. During market hours, the real-time Bats price displays and new trade updates are updated on the page (as indicated by a flash). Volume always reflects consolidated markets.
https://www.barchart.com/stocks/quotes/TBRA
We are reiterating a Buy rating on the common stock of Tobira Therapeutics with an updated price target (intrinsic value) of $34.88. Figure 1: Tobira Therapeutics, common stock price chart (from Bloomberg.com). Discussion of one-year results of phase 2b (CENTAUR) trial (source): This clinical trial tested Cenicriviroc (CVC), an inhibitor of CCR2 and CCR5, vs. placebo in NASH patients with high-risk NASH population and liver fibrosis.
https://seekingalpha.com/article/3991423-buying-tobira-therapeutics-failed-phase-2-nash-trial
Company Profile. Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. The firm's products include Cenicriviroc (CVC) and Evogliptin (EVO).
http://thestockmarketwatch.com/stock/?stock=RGDO
Harwood Feffer LLP Announces Investigation Of Tobira Therapeutics, Inc. Tobira Therapeutics Reaches Analyst Target Price. In recent trading, shares of Tobira Therapeutics Inc have crossed above the average analyst 12-month target price of $19.00, changing hands for $38.91/share.
https://www.thestreet.com/quote/TBRA.html
CVC is a once-daily pill with well-established safety and tolerability in approximately 580 subjects dosed in completed Phase 1 and Phase 2 trials, including a pharmacokinetics and safety study in subjects with liver cirrhosis and 115 HIV type 1, or HIV-1, infected subjects on treatment for up to 48 weeks.
http://www.nasdaq.com/markets/ipos/company/tobira-therapeutics-inc-754412-75811
For US Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more. Most Recent Earnings figures are based on Non-GAAP income from continuing operations. Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares.
https://www.barchart.com/stocks/quotes/TBRA
The deal is expected to close by year-end. Tobira shares were halted permarket for the news, while Allergan shares were not yet active. Allergan stock has shed 22% in the year so far, while the S&P 500 SPX, -0.17% has gained 4.7%.
http://www.marketwatch.com/story/allergan-to-buy-tobira-in-deal-valued-at-up-to-17-billion-2016-09-20
We are reiterating a Buy rating on the common stock of Tobira Therapeutics with an updated price target (intrinsic value) of $34.88 using sum-of-the parts, enterprise DCF method. Tobira Therapeutics (NASDAQ: TBRA) announced the one-year results of a Phase 2 (CENTAUR) clinical trial in patients with non-alcoholic steato-hepatitis (NASH) on July 25.
https://seekingalpha.com/article/3991423-buying-tobira-therapeutics-failed-phase-2-nash-trial
tobira stock price
The stock price of Tobira is $34.88. Tobira stock price is $34.88.